Results 181 to 190 of about 34,445,663 (284)

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist. [PDF]

Clin Pharmacol Ther
Morse BL, Coutant DE, Ma X, Raha S, Aithal K, Nicoll C, Rougée LRA, Bhattachar S.   +7 more
europepmc   +1 more source

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, EarlyView.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on retinal endothelial function and oxidative stress during sepsis. [PDF]

Front Pharmacol
Böhm EW, Kouchek Zadeh J, Omran W, Arad T, Pfeiffer N, Wagner FM, Patzak A, Oelze M, Daiber A, Helmstädter J, Steven S, Gericke A.   +11 more
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy. [PDF]

Front Urol
Huang SC, Cheng WY, Hou CY, Wu JY, Lai CC, Tseng WH.   +5 more
europepmc   +1 more source

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

British Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli, Alessia Campagna, Barbara Eramo, Christian Sepe, Annarita Zuena, Silvana Gaetani, Adele Romano   +6 more
wiley   +1 more source

The Trojan horse of off-label glucagon-like peptide-1 receptor agonist use: Protecting patients through responsible practice. [PDF]

J Int Med Res
Belančić A, Jelaković B.
europepmc   +1 more source

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

British Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan, Rwdah Mohamed Alameri, Yasir S. Raouf, Damien Maurel, Naiem Ahmad Wani, Anatoliy Shmygol, Irfa Anwar, Heng B. See, Elizabeth K. M. Johnstone, Elodie Dupuis, Eric Trinquet, Kevin D. G. Pfleger, Emilia Oueis, Mohammed Akli Ayoub   +13 more
wiley   +1 more source

Depression following the initiation of glucagon-like-peptide-1 receptor agonist therapy: A multinational self-controlled case series study. [PDF]

J Intern Med
Yan VKC, Peng ZY, Wong VKC, Wong ICK, Chan EWY, Ou HT, Wan EYF.   +6 more
europepmc   +1 more source

The dual incretin agonist tirzepatide blunts nicotine‐induced behaviours and neurochemistry in male mice

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Nicotine dependence remains one of the leading causes of morbidity and mortality worldwide, with high relapse rates and post‐cessation weight gain representing persistent barriers to sustained abstinence. The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have ...
Christian E. Edvardsson, Thaynnam A. Emous, Sarah Witley, Mia Ericson, Louise Adermark, Elisabet Jerlhag   +5 more
wiley   +1 more source